The SABER® and Cloud™ Injectable Depot Systems
  ORADUR® Oral Delivery System
  TRANSDUR® Transdermal Technology System
  DURIN® System
  Localized Drug Delivery
  Patents
  Publications


SABER® has the potential to deliver drugs from 1 day to 3 months from a single injection. Bioconpatible excipients are added to the SABER® formulation prior to injection to provide ease of administration. After injection, the excipients diffuse, leaving a viscous deposit.
SABER® has the potential to deliver drugs from 1 day to 3 months from a single injection. Bioconpatible excipients are added to the SABER® formulation prior to injection to provide ease of administration. After injection, the excipients diffuse, leaving a viscous deposit.





Our bioerodible injectable depot systems originated with our SABER system, but has come to encompass a variety of proprietary formulations that may include materials such as sucrose acetate isobutyrate (SAIB), release rate modifying excipients and/or bioerodible polymers to achieve the delivery of drugs for periods of days to months from a single injection. We are researching and developing a variety of controlled-release products based on the SABER technology and our other bioerodible injectable depot approaches. Based on research and development work to date, our bioerodible injectable depot technology has shown the following advantages:

Peptide/Protein Delivery—The chemical nature of our bioerodible injectable depot systems tend to repel water and body enzymes from its interior and thereby stabilizes proteins and peptides. For this reason, we believe that bioerodible injectable depot systems are well suited as a platform for biotechnology therapeutics based on proteins and peptides.
Less Burst—Typically, controlled release injections are associated with an initial higher release of drug immediately after injection (also called “burst”). Animal and human studies have shown that our bioerodible injectable depots can be associated with less post-injection burst than is typically associated with other commercially available injectable controlled release technologies.
High Drug Concentration—Drug concentration in our bioerodible injectable depot formulations can be as high as 30%, considerably greater than is typical with other commercially available injectable controlled release technologies. As a result, smaller injection volumes are possible with this technology.
Ease of Administration—Prior to injection, our bioerodible injectable depot formulations are fairly liquid and therefore can be injected through small needles. Additionally, because of the higher drug concentration of our bioerodible injectable depot formulations, less volume is required to be injected. Small injection volumes and more liquid solutions are expected to result in easier, less painful administration.
Strong Patent Protection—Our bioerodible injectable depot technology is covered by United States and foreign patents.
Ease of Manufacture—Compared to microspheres and other polymer-based controlled release injectable systems, our bioerodible injectable depot formulations are readily manufacturable at low cost.

The SABER technology is the basis of POSIDUR, for which a New Drug Application (NDA) was filed with the FDA and for which a Complete Response Letter was received on February 12, 2014. The SABER Technology is also the basis for Relday, which is in a Phase I in the U.S. In our clinical studies thus far, our bioerodible injectable depot formulations have been observed to be safe and well-tolerated, and no significant side effects or adverse events have been reported.

The SABER Technology is also the basis for SucroMate™ Equine, an injectable animal health drug utilizing our SABER technology to deliver the peptide deslorelin. This is the first FDA approved SABER injectable product and it was launched in 2011 by our collaborator, CreoSalus, Inc.

Download the SABER® Fact Sheet (.PDF).

Back to top



 
 © 2000-2014 DURECT Corporation
Last updated: July 30, 2014
Search     Contact     Site Index     Legal Notice     Privacy Policy